Reviews:
LncRNAs: key players and novel insights into diabetes mellitus
Metrics: PDF 2562 views | HTML 6220 views | ?
Abstract
Xiaoyun He1,2,*, Chunlin Ou3,*, Yanhua Xiao1, Qing Han1, Hao Li4 and Suxian Zhou1
1Department of Endocrinology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
2Department of Endocrinology, Xiangya Hospital, Central South University, Changsha 410008, China
3Cancer Research Institute, Central South University, Changsha 410078, China
4Department of Neurology, Affiliated Hospital of Guilin Medical University, Guilin 541001, China
*These authors contributed equally to this work and share co-first authors
Correspondence to:
Suxian Zhou, email: [email protected]
Keywords: LncRNAs, diabetes mellitus, pancreatic β cells, insulin resistance, epigenetic regulation
Received: March 29, 2017 Accepted: July 19, 2017 Published: August 04, 2017
ABSTRACT
Long non-coding RNAs (LncRNAs) are a class of endogenous RNA molecules, which have a transcribing length of over 200 nt, lack a complete functional open reading frame (ORF), and rarely encode a functional short peptide. Recent studies have revealed that disruption of LncRNAs levels correlates with several human diseases, including diabetes mellitus (DM), a complex multifactorial metabolic disorder affecting more than 400 million people worldwide. LncRNAs are emerging as pivotal regulators in various biological processes, in the progression of DM and its associated complications, involving pancreatic β-cell disorder, insulin resistance, and epigenetic regulation, etc. Further investigation into the mechanisms of action of LncRNAs in DM will be of great value in the thorough understanding of pathogenesis. However, prior to successful application of LncRNAs, further search for molecular biomarkers and drug targets to provide a new strategy for DM prevention, early diagnosis, and therapy is warranted.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19921